RNS Number : 3537W
ReGen Therapeutics PLC
10 June 2008
10 June 2008
Colostrinin*/CogniSure* Sales Update - Estimated Market Value* $2.2m in First Half of
2008
ReGen Therapeutics Plc ('ReGen') announces that it is providing guidance on the market
value of Colostrinin*/CogniSure* ordered by
Metagenics Inc., its licensee and distribution partner for the USA, Australasian and Canadian
markets, in the first half of 2008. Based on
the number of kilos ordered by Metagenics, and assuming all are sold, ReGen estimates that the
market value of these orders would be
approximately $2.2m
Percy Lomax, Executive Chairman of ReGen commented "We are delighted with the progress
that Colostrinin*/CogniSure* has made since its
launch into the professional market. We believe this is a substantial achievement given that
it is less than a year since the product was
first launched in Australia and it has only been on the US market for eight months.
For further information, please contact:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396
David Scott/Nick Bealer
Alexander David
Tel: 020 7448 9800
Adrian Duffield/Jon Davies
College Hill Associates
Tel: 020 7457 2020
Note:
*Market value is the total sales value at the price per unit paid by the consumer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFMMLTMMMBMLP
|